Home › NDC Lookup › RxCUI directory › RxCUI 379804

Glipizide 2.5 MG Oral Tablet — RxCUI 379804

RxNorm drug concept · Semantic clinical drug
RxCUI 379804 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 17 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI379804
Official nameGlipizide 2.5 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped5
Package NDCs mapped17
Reported Medicaid activity (SDUD)57,331 prescriptions · 45 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Glipizide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Glipizide is used to help lower blood sugar in adults with type 2 diabetes. It works by telling your pancreas to release more insulin after you eat. It's meant to be used alongside...
  • What exactly is glipizide for, and how does it help my diabetes?
  • Timing really does matter with this one. If you're taking the regular tablet, aim to take it about 30 minutes before a meal — that way it's working right when your blood sugar star...
  • When should I take my glipizide, and does it matter if I eat?
📖 Read our full Glipizide guide →

🕸️ Concept Web — How Glipizide 2.5 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Glipizide 2.5 MG Oral Tablet RxCUI 379804

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Glipizide 4821
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Glipizide Oral Tablet 372320
    • Glipizide Oral Product 1165207
    • Glipizide Pill 1165208
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Glipizide 2.5 MG 330349

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Glipizide 2.5 MG SCDC · 330349
  • Glipizide Oral Tablet SCDF · 372320
  • Glipizide Oral Product SCDG · 1165207
  • Glipizide Pill SCDG · 1165208

📦 FDA Products & Package NDCs

5 products · 17 package NDCs
17 package NDCs map to RxCUI 379804 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
52817-0385-10 100 TABLET in 1 BOTTLE (52817-385-10) Glipizide TruPharma LLC 2023-10-03
52817-0385-50 500 TABLET in 1 BOTTLE (52817-385-50) Glipizide TruPharma LLC 2023-10-03
72888-0115-00 1000 TABLET in 1 BOTTLE (72888-115-00) Glipizide Advagen Pharma Limited 2023-10-03
72888-0115-01 100 TABLET in 1 BOTTLE (72888-115-01) Glipizide Advagen Pharma Limited 2023-10-03
72888-0115-05 500 TABLET in 1 BOTTLE (72888-115-05) Glipizide Advagen Pharma Limited 2023-10-03
72888-0115-30 30 TABLET in 1 BOTTLE (72888-115-30) Glipizide Advagen Pharma Limited 2023-10-03
72888-0116-00 1000 TABLET in 1 BOTTLE (72888-116-00) Glipizide Advagen Pharma Limited 2023-10-03
72888-0116-01 100 TABLET in 1 BOTTLE (72888-116-01) Glipizide Advagen Pharma Limited 2023-10-03
72888-0116-05 500 TABLET in 1 BOTTLE (72888-116-05) Glipizide Advagen Pharma Limited 2023-10-03
72888-0116-30 30 TABLET in 1 BOTTLE (72888-116-30) Glipizide Advagen Pharma Limited 2023-10-03
72888-0117-00 1000 TABLET in 1 BOTTLE (72888-117-00) Glipizide Advagen Pharma Limited 2023-10-03
72888-0117-01 100 TABLET in 1 BOTTLE (72888-117-01) Glipizide Advagen Pharma Limited 2023-10-03
72888-0117-05 500 TABLET in 1 BOTTLE (72888-117-05) Glipizide Advagen Pharma Limited 2023-10-03
72888-0117-30 30 TABLET in 1 BOTTLE (72888-117-30) Glipizide Advagen Pharma Limited 2023-10-03
72888-0231-00 1000 TABLET in 1 BOTTLE (72888-231-00) Glipizide Advagen Pharma Limited 2026-02-04
72888-0231-01 100 TABLET in 1 BOTTLE (72888-231-01) Glipizide Advagen Pharma Limited 2026-02-04
72888-0231-05 500 TABLET in 1 BOTTLE (72888-231-05) Glipizide Advagen Pharma Limited 2026-02-04
Observed labelers: Advagen Pharma Limited (15) · TruPharma LLC (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.